Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases

[31] Suh J(2015)Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival PLoS ONE 10 e0124658-177

[32] Ngo N(2011)Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53 Br J Cancer 105 272-584

[33] Kwa M(2019)Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab Appl Immunohistochem Mol Morphol 27 92-1493

[34] Troxel AB(2017)Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma In Situ, metastatic tumor deposits and areas for further research Adv Anat Pathol 24 235-1016

[35] Chae YK(2017)Association of γH2AX at diagnosis with chemotherapy outcome in patients with breast cancer Theranostics 7 945-1828

[36] Kurzrock R(2018)The positive relationship between γH2AX and PD-L1 expression in lung squamous cell carcinoma In vivo (Athens, Greece) 32 171-511

[37] Patel SP(2019)PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review Breast Cancer Res Treat 174 571-342

[38] Bartkova J(2015)PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes Ann Oncol 26 1488-821

[39] Horejsí Z(2021)Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study J Natl Cancer Inst 113 1005-1100

[40] Koed K(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 396 1817-1288

[31] Suh J(2015)Distinguishing Low-Risk Luminal A Breast Cancer Subtypes with Ki-67 and p53 Is More Predictive of Long-Term Survival PLoS ONE 10 e0124658-177

[32] Ngo N(2011)Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53 Br J Cancer 105 272-584

[33] Kwa M(2019)Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab Appl Immunohistochem Mol Morphol 27 92-1493

[34] Troxel AB(2017)Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the international immunooncology biomarkers working group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma In Situ, metastatic tumor deposits and areas for further research Adv Anat Pathol 24 235-1016

[35] Chae YK(2017)Association of γH2AX at diagnosis with chemotherapy outcome in patients with breast cancer Theranostics 7 945-1828

[36] Kurzrock R(2018)The positive relationship between γH2AX and PD-L1 expression in lung squamous cell carcinoma In vivo (Athens, Greece) 32 171-511

[37] Patel SP(2019)PD-L1 expression in breast cancer: expression in subtypes and prognostic significance: a systematic review Breast Cancer Res Treat 174 571-342

[38] Bartkova J(2015)PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes Ann Oncol 26 1488-821

[39] Horejsí Z(2021)Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study J Natl Cancer Inst 113 1005-1100

[40] Koed K(2020)Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Lancet 396 1817-1288